Search results
Showing 251 to 300 of 2008 results for news
Awaiting development Reference number: GID-TA11968 Expected publication date: TBC
People's experience using adult social care services (QS182)
This quality standard covers the experience of adults using social care services. It applies to all settings where people use social care services, including people's own homes, residential care and community settings. Its aim is to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care. It describes high-quality care in priority areas for improvement.
View quality statements for QS182Show all sections
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]
Awaiting development Reference number: GID-TA11964 Expected publication date: TBC
Awaiting development Reference number: GID-TA11942 Expected publication date: TBC
Awaiting development Reference number: GID-TA11987 Expected publication date: TBC
Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]
Awaiting development Reference number: GID-TA11951 Expected publication date: TBC
Awaiting development Reference number: GID-TA11976 Expected publication date: TBC
Awaiting development Reference number: GID-TA11986 Expected publication date: TBC
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]
Awaiting development Reference number: GID-TA11874 Expected publication date: TBC
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]
Awaiting development Reference number: GID-TA11937 Expected publication date: TBC
Awaiting development Reference number: GID-TA12031 Expected publication date: TBC
Awaiting development Reference number: GID-TA12030 Expected publication date: TBC
Older people with social care needs and multiple long-term conditions (NG22)
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.
Xanomeline tartrate–trospium chloride for treating schizophrenia [ID6716]
Awaiting development Reference number: GID-TA11925 Expected publication date: TBC
CM-AT for behaviours associated with autism in children and young people [ID6731]
Awaiting development Reference number: GID-TA11955 Expected publication date: TBC
Awaiting development Reference number: GID-TA12008 Expected publication date: TBC
Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]
Awaiting development Reference number: GID-TA12004 Expected publication date: TBC
Awaiting development Reference number: GID-TA12000 Expected publication date: TBC
Povorcitinib for treating non-segmental vitiligo [TSID12388]
Awaiting development Reference number: GID-TA12019 Expected publication date: TBC
Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [TSID12395]
Awaiting development Reference number: GID-TA12013 Expected publication date: TBC
GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]
Awaiting development Reference number: GID-TA12009 Expected publication date: TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]
Awaiting development Reference number: GID-TA11953 Expected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]
Awaiting development Reference number: GID-TA11912 Expected publication date: TBC
Awaiting development Reference number: GID-TA12018 Expected publication date: TBC
Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]
Awaiting development Reference number: GID-TA12017 Expected publication date: TBC
Awaiting development Reference number: GID-TA12015 Expected publication date: TBC
Awaiting development Reference number: GID-TA12011 Expected publication date: TBC
Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]
Awaiting development Reference number: GID-TA12007 Expected publication date: TBC
Awaiting development Reference number: GID-TA12005 Expected publication date: TBC
Awaiting development Reference number: GID-TA12003 Expected publication date: TBC
Awaiting development Reference number: GID-TA12001 Expected publication date: TBC
Awaiting development Reference number: GID-TA11980 Expected publication date: TBC
AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]
Awaiting development Reference number: GID-TA11962 Expected publication date: TBC
Awaiting development Reference number: GID-TA12033 Expected publication date: TBC
Awaiting development Reference number: GID-TA12036 Expected publication date: TBC
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]
Awaiting development Reference number: GID-TA11926 Expected publication date: TBC
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]
Awaiting development Reference number: GID-TA11917 Expected publication date: TBC
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Awaiting development Reference number: GID-TA11921 Expected publication date: TBC
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]
Awaiting development Reference number: GID-TA11988 Expected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]
Awaiting development Reference number: GID-TA11930 Expected publication date: TBC
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.